Association Between Telomere Length and Cardiovascular Risk: Pharmacological Treatments Affecting Telomeres and Telomerase Activity-Reference-Cited by-同舟云学术

Association Between Telomere Length and Cardiovascular Risk: Pharmacological Treatments Affecting Telomeres and Telomerase Activity

Published:2022-11 Issue:6 Volume:20 Page:465-474
ISSN:1570-1611
Container-title:Current Vascular Pharmacology
language:en
Short-container-title:CVP

Author:

Zafirovic Sonja¹^ORCID,Macvanin Mirjana¹^ORCID,Stanimirovic Julijana¹^ORCID,Obradovic Milan¹^ORCID,Radovanovic Jelena¹^ORCID,Melih Irena²,Isenovic Esma¹^ORCID

Affiliation:

1. Department of Radiobiology and Molecular Genetics, VINČA Institute of Nuclear Sciences - National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia

2. Faculty of Stomatology, Pancevo, University Business Academy, 21000 Novi Sad, Serbia.

Abstract

Abstract: Telomeres represent the ends of chromosomes, and they are composed of an extensive number of – TTAGGG nucleotide sequence repeats in humans. Telomeres prevent chromosome degradation, participate in stabilization, and regulate the DNA repair system. Inflammation and oxidative stress have been identified as important processes causing cardiovascular disease and accelerating telomere shortening rate. This review investigates the link between telomere length and pathological vascular conditions from experimental and human studies. Also, we discuss pharmacological treatments affecting telomeres and telomerase activity.

Funder

Ministry of Education, Science and Technological Development of the Republic of Serbia

Publisher

Bentham Science Publishers Ltd.

Subject

Cardiology and Cardiovascular Medicine,Pharmacology

Reference133 articles.

1. Serrano A.L.; Andrés V.; Telomeres and cardiovascular disease: Does size matter? Circ Res 2004,94(5),575-584

2. Fuster J.J.; Andrés V.; Telomere biology and cardiovascular disease. Circ Res 2006,99(11),1167-1180

3. Pinto A.R.; Li H.; Nicholls C.; Liu J.P.; Telomere protein complexes and interactions with telomerase in telomere maintenance. Front Biosci 2011,16(1),187-207

4. Hoffmann J.; Richardson G.; Haendeler J.; Altschmied J.; Andrés V.; Spyridopoulos I.; Telomerase as a therapeutic target in cardiovascular disease. Arterioscler Thromb Vasc Biol 2021,41(3),1047-1061

5. Kolovou G.; Bilianou H.; Marvaki A.; Mikhailidis D.P.; Aging men and lipids. Am J Men Health 2011,5(2),152-165

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. P14-04 The impact of short telomere length on cardiac disease;Toxicology Letters;2024-09

2. Association of leukocyte telomere attrition in coronary artery disease in Pakistani population: A case-control study with meta-analysis;Clinica Chimica Acta;2023-07